Fig. 3From: Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish populationNet monetary benefit analysis for subgroups. Figure notes: *Severity of airflow limitation based on 2011–2014 GOLD criteria; ^Based on 2015 GOLD staging system. GOLD: global initiative for chronic obstructive lung disease classificationBack to article page